![Table I from Public Assessment Report Decentralised Procedure Plenvu powder for oral solution (Macrogol 3350, sodium ascorbate, sodium sulfate anhydrous, ascorbic acid, sodium chloride, potassium chloride) Procedure No: UK/H/6370/001/DC UK Licence No: Table I from Public Assessment Report Decentralised Procedure Plenvu powder for oral solution (Macrogol 3350, sodium ascorbate, sodium sulfate anhydrous, ascorbic acid, sodium chloride, potassium chloride) Procedure No: UK/H/6370/001/DC UK Licence No:](https://d3i71xaburhd42.cloudfront.net/aec9499de72e7fa0cbc1a7371f123f67549a8158/29-TableI-1.png)
Table I from Public Assessment Report Decentralised Procedure Plenvu powder for oral solution (Macrogol 3350, sodium ascorbate, sodium sulfate anhydrous, ascorbic acid, sodium chloride, potassium chloride) Procedure No: UK/H/6370/001/DC UK Licence No:
![Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database | Scientific Reports Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-10777-w/MediaObjects/41598_2022_10777_Fig1_HTML.png)